Background. Progranulin (PGRN) is an important immunomodulatory factor in a variety of inflammatory diseases. However, its role in pulmonary immunity against bacterial infection remains unknown.
Lower respiratory tract infection is the fourth most common cause of death according to the findings of the Global Burden of Disease Study 2013 [1] . Bacteria are the most frequent cause of community-acquired pneumonia. Effective treatment of bacterial pneumonia is more challenging due to the rising specter of antimicrobial resistance [2] . Pulmonary immunity plays a central role in the defense against microbes in the lung, where a variety of inflammatory mediators, including cytokines, chemokines, and growth factors regulate infection and immunity [3] . Expanding our knowledge about pulmonary immunity and elucidating the cellular and molecular responses to microbes in the lung will identify new opportunities for combating bacterial pneumonia.
Progranulin (PGRN) is an autocrine growth factor expressed in a variety of tissues and cell types. Progranulin is a secreted protein, and it functions at the cytoplasmic and nuclear level. So far, >20 PGRN-binding proteins have been reported [4] . The interaction between PGRN and its binding partners contributes to the pathogenesis of a variety of inflammatory diseases, including cancers [5] , autoimmune diseases [6, 7] , disorders of the nervous system [8] , cardiovascular diseases [9] , diabetes, and infectious diseases [10] . Progranulin has proinflammatory or anti-inflammatory activity depending on the stage and components involved in the tissue microenvironment, which may either be protective or harmful to the host [4] .
Our group previously reported increased production of PGRN in patients with sepsis [11] . In this study, we aimed to characterize the role of PGRN in pulmonary immunity against bacterial infections. For this, we first determined the extent of PGRN release in patients with community-acquired pneumonia, and then we compared host immune response in PGRN −/− (PGRN-deficient) and normal wild-type (WT) mice using our established model of bacterial pneumonia induced by intranasal injection of Pseudomonas aeruginosa or Staphylococcus aureus. data, such as the counts of white blood cells (WBC), the levels of C-reaction proteins (CRPs), and microbial culture results, were recorded. Patients with malignancy and organ transplantation, human immunodeficiency virus-infected patients, and patients receiving immunosuppressive agents in the previous 8 weeks were excluded from the study. Control samples were obtained from 19 healthy donors. In addition, 11 patients from the total cohort of 25 pneumonia patients and 7 control individuals from the total cohort of 19 control donors donated bronchoalveolar lavage fluid (BALF). The BALF was collected according to a standardized protocol using an Olympus BF 1T20 fiberoptic bronchoscope (Olympus Europe). All characteristics of patients and control subjects are summarized in Supplementary Table 1 . This protocol was approved by the Clinical Research Ethics Committee of Chongqing Medical University, and informed consent was obtained from all participants according to the Declaration of Helsinki.
Mouse Studies
In vivo experiments were performed using age-and sexmatched WT and PGRN −/− mice (Jackson Laboratories). Mice were anesthetized with 100 mg/kg of ketamine and 5 mg/kg of xylazine and then infected with S. aureus 502A (5 × 10 7 colony-forming units [CFUs] in 50 μL of phosphate-buffered saline [PBS]) or P. aeruginosa PAK (1 × 10 7 or 5 × 10 7 CFUs in 50 μL of PBS) intranasally, which mimics the natural route of infection during human pneumonia. Pseudomonas aeruginosa PAK has been widely used to induce P. aeruginosa pneumonia [14] [15] [16] [17] , whereas S. aureus 502A has been widely used to induce S. aureus pneumonia [14, 18] . In survival studies, survival was monitored for up to 10 days after infection. All animal experiments were done in accordance with the Institutional Animal Care and Use Committee's guidelines at the Chongqing Medical University.
Preparation of Mouse Samples and Lung Homogenates
At designated time points, the mice were euthanized by carbon dioxide inhalation. Blood was drawn into heparinized tubes, BALF was obtained, organs were removed aseptically and homogenized in 4 volumes of sterile isotonic saline using a tissue homogenizer (Biospec Products), and 0.9-1.0 mL of BALF were retrieved per mouse. Lungs were then removed from euthanized animals, and leukocytes were prepared as previously described [19] . Briefly, lung slurries were enzymatically digested for 30 minutes at 37°C. The total lung cell suspension was pelleted, resuspended, and spun through a 40% Percoll gradient to enrich for leukocytes. Cell counts and viability were determined using Trypan blue exclusion counting on a hemacytometer. Cytospin slides were prepared and stained with a Wright-Giemsa stain.
Histology
Lungs were inflated with 0.5% agarose under water pressure and fixed in 10% buffered formalin for 24 hours. Next, formalin-fixed, paraffin-embedded, 6-μm sections of lungs were used for immunohistochemistry by hematoxylin-and-eosin staining. Lung pathology scores were determined as described previously [11, 20] : the entire lung surface was analyzed by a blinded pathologist with respect to the following parameters: bronchitis, edema, interstitial inflammation, intra-alveolar inflammation, pleuritis, endothelialitis, and percentage of the lung surface demonstrating confluent inflammatory infiltrate.
Determination of Lung and Plasma Bacterial Burdens
At the designated time points, plasma was collected, the right ventricle was perfused with 1 mL of PBS, and the lungs were then removed aseptically and placed in 1 mL of sterile saline. The tissues were then homogenized with a tissue homogenizer under a vented hood. Serial 1:5 dilutions of both lung homogenates and plasma were made. Ten microliters of each dilution were plated on soy-base blood agar plates to determine bacterial CFUs.
Protein Assays
The levels of PGRN were determined by mouse progranulin enzyme-linked immunosorbent assay (ELISA) kit (RayBiotech) or human progranulin quantikine ELISA kit (R&D systems). Assessment of inflammatory cytokines or chemokines, including tumor necrosis factor α (TNF-α), interleukin 6 (IL-6), interferon γ (IFN-γ), interleukin 10 (IL-10), CXCL1, and CCL2 was performed using ELISA kits (Biolegend) according to the manufacturers' instructions.
Flow Cytometry Assays
Cells were washed in PBS, pelleted, and subsequently stained for flow cytometry. Cell counts were characterized accordingly with PerCP-conjugated anti-CD45, APC-conjugated antiCD11b, FITC-conjugated anti-Ly6G, and PE-cy5-conjugated anti-F4/80 monoclonal antibodies (BD Pharmingen). The absolute numbers of CD11b + Ly6G + neutrophils and CD11b + F4/80 + macrophages were then quantified by dividing the number of positive cellular events by the number of bead events and multiplying the result by the bead concentration using FACScan flow cytometer (Becton Dickinson). Absolute numbers per lung were derived from the pooled sample of 5 biopsies.
In Vivo Administration of Recombinant Progranulin
For in vivo PGRN reconstitutions, each mouse was injected intranasally with 10 μg of mouse recombinant PGRN (R&D Systems) resuspended in 0.1% bovine serum albumin (BSA) in PBS 2 hours after bacterial infection. The recombinant PGRN contained <1.0 U endotoxin per 1 μg, as determined by Limulus amoebocyte lysate assay (R&D Systems). Control animals received PBS and 0.1% BSA.
Statistical Analysis
Data are expressed as box-and-whisker diagrams unless indicated otherwise. Differences between patients and volunteers or between WT and PGRN −/− mice were analyzed by MannWhitney U test. Survival was compared by Kaplan-Meier analysis followed by a log rank test. Values of P < .05 were considered statistically significant.
RESULTS

Elevated Progranulin Levels in Human Patients With Pneumonia
To obtain a first insight into PGRN production during pneumonia, we measured PGRN levels in BALF from patients with community-acquired pneumonia requiring treatment. Patients with community-acquired pneumonia displayed significantly elevated levels of PGRN in BALF compared with controls without lung disease Figure 1A ). Patients with community-acquired pneumonia also showed significantly increased serum PGRN levels compared with normal serum values ( Figure 1B ). There was no correlation between PGRN levels and the type of microbial species or any other clinical and biologic features.
Increased Progranulin Levels During Murine Bacterial Pneumonia
To further investigate the potential role of PGRN in bacterial pneumonia, we intranasally infected WT mice with P. aeruginosa or S. aureus and measured local and systemic PGRN concentrations. Elevated local levels of PGRN were measured in whole-lung homogenates after infection ( Figure 2A ). In sera, PGRN was also strongly enhanced after infection ( Figure 2B ). These data indicate that murine pneumococcal pneumonia resembles human community-acquired pneumonia with regard to upregulated pulmonary and systemic release of PGRN.
Impaired Host Defense in Progranulin-Deficient mice During
Pseudomonas aeruginosa Pneumonia
To investigate a potential role for PGRN in the outcome of bacterial pneumonia, we intranasally infected WT and PGRN −/− mice with P. aeruginosa (1 × 10 7 CFUs). Progranulindeficient mice have been widely used to study the role of PGRN in human diseases [6, 8, 9, 10, 11, 21, 22] . In fact, PGRN −/− mice demonstrated normal hematopoietic development and no other defects in other organs, and all peripheral blood cell counts, lymph nodes, and anatomy were normal (data not shown). Here, PGRN −/− mice showed a significantly decreased survival rate compared with WT controls ( Figure 3A ). Experiments were also performed to determine whether the decreased survival observed in PGRN −/− animals was due to impaired bacterial clearance after P. aeruginosa bacterial challenge. We examined lung and blood bacterial burden in PGRN −/− and WT mice after intranasal P. aeruginosa challenge. At 24 hours after P. aeruginosa infection, PGRN −/− animals had significantly increased bacterial counts in both the lung and blood, as compared with their WT counterparts ( Figure 3B ). In line with an increased mortality rate and a decreased bacterial clearance rate, PGRN −/− mice presented with lethargy and piloerection as soon as 24 hours after P. aeruginosa infection, which were clinical signs of severe pneumonia ( Figure 3C ).
Increased Mortality and Reduced Bacterial Clearance in Progranulin-
Deficient Mice During Staphylococcus aureus Pneumonia
We also studied the contribution of PGRN to host defense during S. aureus pneumonia. Remarkably, lack of PGRN significantly decreased survival after intranasal challenge with S. aureus (5 x 10 7 CFUs) ( Figure 4A ). Progranulin deficiency reduced the clearance of S. aureus from the airways to a significant extent, and staphylococcal loads were also significantly higher in the blood from PGRN −/− mice when compared with those from WT mice ( Figure 4B ). As with P. aeruginosa infection, PGRN −/− mice also showed clinical signs of severe pneumonia at 24 hours after S. aureus infection ( Figure 4C ). Together, these data indicate that PGRN deficiency impaired bacterial clearance in the lungs, thereby contributing to accelerated lethality during bacterial pneumonia. Patients with community-acquired pneumonia had an increase of progranulin levels. A, Progranulin levels in bronchoalveolar lavage fluid (BALF) from control donors (n = 7) and patients with community-acquired pneumonia (n = 11). B, Progranulin levels in sera from patients with community-acquired pneumonia (n = 25) and control subjects (n = 19). *P < .05 when compared with controls (Mann-Whitney U test). Abbreviations: BALF, bronchoalveolar lavage fluid; PGRN, progranulin. 
Enhanced Lung Pathology in Progranulin-Deficient Mice During Bacterial Pneumonia
To further elaborate on the mechanism underlying decreased survival of PGRN −/− mice, we studied lung pathology in P. aeruginosa pneumonia as a model. Already at 6 hours, loss of PGRN resulted in aggravated lung pathology with more advanced signs of alveolar hemorrhage ( Figure 5A ). Lung pathology scores were significantly higher in PGRN −/− mice at 24 hours after infection, with more hemorrhage, endothelialitis, and edema ( Figure 5B ). Thus, our data demonstrate that PGRN deficiency aggravated bacteria-induced acute pneumonia and lung injury.
Lung Cytokine and Chemokine Levels in Progranulin-Deficient Mice During Bacterial Pneumonia
Previous investigations have shown that PGRN regulated the expression of inflammatory mediators [4, 6, 10, 11] , and pneumonia is characterized by a local and systemic production of well-known cytokines and chemokines, including IL-6, IFN-γ, TNF-α, CCL2, CXCL1, and IL-10 [14, 19, [23] [24] [25] [26] . At the early time after bacterial pneumonia, acute pulmonary inflammation occurred, and thus these cytokines and chemokines increased rapidly. Then, as with the resolution of acute lung inflammatory reactions, these inflammatory mediators decreased [26, 27] . We therefore examined whether PGRN modulated the expression of these cytokines and chemokines in the lungs of mice at the early (6 hours) and later (24 hours) times when they were intranasally challenged with P. aeruginosa. In whole-lung homogenates, PGRN −/− mice displayed significantly increased TNF-α levels after 6 hours ( Figure 6A) . Surprisingly, PGRN −/− mice had significantly decreased pulmonary CXCL1 levels after 6 hours, as well as reduced pulmonary CCL2 production, which reached statistical significance after 24 hours ( Figure 6A ). However, plasma levels of cytokines and chemokines did not differ between WT and PGRN −/− mice at 6 or 24 hours after infection ( Figure 6B ).
Lung Leukocyte Recruitment in Progranulin-Deficient Mice During
Bacterial Pneumonia
The most prominent differences in cytokine and chemokine production between PGRN −/− and WT mice during bacterial (1 × 10 7 CFUs; n = 15 per group). **P < .01 when compared with WT mice (Kaplan-Meier analysis followed by log-rank tests). B, Bacterial loads in the lung and blood 24 hours after intranasal inoculation with P. aeruginosa (1 × 10 7 CFUs; n = 5 per group). *P < .05, ***P < .001 when compared with WT mice (Mann-Whitney U test). C, Clinical appearance of PGRN −/− and WT mice 24 hours after intranasal infection with P. aeruginosa (1 x 10 7 CFUs). Abbreviations: CFU, colony-forming unit; PGRN, progranulin; WT, wild-type.
pneumonia were observed in the levels of chemokines that facilitate lung neutrophil and macrophage influx, namely, CXCL1 and CCL2, respectively. Experiments were then performed to characterize the nature of infiltrating leukocytes, including neutrophils and macrophages, after P. aeruginosa challenge. As shown in Figure 6C , neutrophil counts were determined by gating on CD11b + Ly6G + cells, and macrophage counts were determined by gating on CD11b + F4/80 + cells according to previous protocols [28] [29] [30] . We observed that PGRN −/− mice had significantly decreased total leukocytes in the lungs compared with WT mice at 6 or 24 hours after infection ( Figure 6D ). We noted a reduced number of lung CD11b + Ly6G + neutrophils, which reached statistical significance in PGRN −/− mice at 24 hours compared with that in WT mice. Furthermore, PGRN −/− animals had a significant decrease in the numbers of CD11b + F4/80 + macrophages in the lungs compared with infected WT mice at 6 or 24 hours after infection. In contrast, we did not observe significant differences in the number of CD3 + lymphocytes after P. aeruginosa infection (data not shown).
Protection Against Bacterial Pneumonia Elicited By Recombinant Progranulin
To determine whether exogenous PGRN would be sufficient to rescue PGRN −/− mice challenged with P. aeruginosa (1 × 10 7 CFUs), we treated mice with recombinant PGRN at the time of bacterial infection. Treatment with recombinant PGRN could significantly decrease mortality ( Figure 7A ) and increase bacterial clearance from the lungs ( Figure 7B ) compared with PGRN −/− mice treated with carrier solution.
Finally, we wished to see the therapeutic effects of recombinant PGRN on bacterial pneumonia in WT mice challenged with P. aeruginosa. Therefore, in separate experiments, WT mice infected with P. aeruginosa (5 × 10 7 CFUs) were treated with a single dose of recombinant PGRN or carrier solution at 2 hours after infection. We observed 100% mortality in WT mice ; n = 10 per group). ***P < .01 when compared with WT mice (Kaplan-Meier analysis followed by log-rank tests). B, Bacterial loads in the lung and blood 24 hours after intranasal inoculation with S. aureus (5 × 10 7 CFUs; n = 5 per group). **P < .01, ***P < .001 when compared with WT mice (Mann-Whitney U test). C, Clinical appearance of PGRN −/− and WT mice 24 hours after intranasal infection with S. aureus (5 × 10 7 CFUs). Abbreviations: CFU, colony-forming unit; PGRN, progranulin; WT, wild-type. treated with carrier solution upon severe pneumonia. However, administration of recombinant PGRN significantly improved the survival rate (40%) in WT mice ( Figure 7C ). Progranulin treatment also significantly increased bacterial clearance from the lungs ( Figure 7D ).
DISCUSSION
Bacterial pneumonia is associated with high morbidity and mortality rates worldwide, and it remains a major challenge for clinicians. Despite our efforts to halt the increase and spread of antimicrobial resistance, bacteria continue to become less susceptible to antibiotics over time [31] . One promising approach involves targeted therapy specific to immune activity [32] . In this study, we observed elevated PGRN levels in the course of clinical and experimental bacterial pneumonia. We also found that PGRN mediated host defense against both Gram-positive and Gram-negative pneumonia, as reflected by decreased bacterial clearance and increased mortality rates in PGRN-deficient mice. Furthermore, PGRN treatment after bacterial infection could protect against pneumonia, suggesting that PGRN is a novel adjuvant therapy in bacterial pneumonia.
We recently reported elevated PGRN levels in clinical and experimental sepsis [11] . However, the production of PGRN in less fulminant models remains to be established. We here demonstrated for the first time that circulating PGRN levels were elevated in patients with community-acquired pneumonia. Notably, PGRN levels were enhanced at the primary site of infection, as detected in BALF. Furthermore, experimentally induced bacterial pneumonia by P. aeruginosa or S. aureus led to upregulated local and systemic release of PGRN in mice, corresponding to the increased PGRN levels in lipopolysaccharide (LPS)-induced lung injury [33] . Serum PGRN levels were also elevated in dermatomyositis patients with acute interstitial lung disease [34] . Thus, increased PGRN plays an immunomodulatory role in the lungs during bacterial pneumonia.
We have shown here that PGRN deficiency enhanced lung pathology and lung injury, decreased bacterial clearance, and increased mortality in Gram-positive and Gram-negative pneumonia, indicating that PGRN acted as a positive regulator for host defense in pulmonary immunity. A major interesting finding in this study is that PGRN −/− mice had lower pulmonary chemokine CCL2 and CXCL1 levels, corresponding to impaired recruitment of macrophages and neutrophils The absolute number of total cells, neutrophils (CD11b + Ly6G + ), and macrophages (CD11b + F4/80 + ) in BALF at 6 or 24 hours after intranasal infection with P. aeruginosa (1 × 10 7 CFUs; n = 5 per group). *P < .05, **P < .01, P < .001 when compared with WT mice at the same time point (Mann-Whitney U test). Abbreviations: IFN-γ, interferon γ; IL-6, interleukin 6; IL-10, interleukin 10; PGRN, progranulin; TNF-α, tumor necrosis factor α; WT, wild-type.
in the lungs. Macrophages and neutrophils are phagocytes critical for host defense, and they are regularly and promptly recruited to the sites of bacterial infection, generating antibacterial functions [35] . We have previously demonstrated that PGRN deficiency led to reduced peritoneal CCL2 production and macrophage influx, but not neutrophil recruitment, in the abdominal cavity during peritoneal sepsis [11] . However, in addition to macrophages, PGRN also mediated neutrophil accumulation in the lungs during bacterial pneumonia, which is consistent with the finding that PGRN increased the accumulation of neutrophils and macrophages in the wound [36] . A recent report has demonstrated that PGRN suppressed neutrophil recruitment into the brain of cerebral ischemia-reperfusion injury [37] . Therefore, the exact function of PGRN varies depending on the stage and components involved in inflammation. In accordance with PGRN not modulating intrinsic antibacterial functions of macrophages and neutrophils on Escherechia coli [11] , we found that preincubation with recombinant PGRN did not influence bacterial phagocytosis and killing in macrophages and neutrophils on P. aeruginosa or S. aureus (data not shown). Therefore, PGRN deficiency worsened the development of bacterial pneumonia, which was due to impaired recruitment of macrophages and neutrophils in the lung, and the reduced number of pulmonary macrophages and neutrophils observed in PGRNdeficient mice may be attributed to a reduction of pulmonary CCL2 and CXCL1. Given the complex regulatory mechanisms of pneumonia during bacterial infections, our data do not preclude the other molecular mechanism involved in this complicated pathological process regulated by PGRN.
Of particular interest in this study is that PGRN administration 2 hours after bacterial pneumonia significantly improved survival compared with vehicle-treated control animals, indicating that PGRN administration is a viable therapeutic modality in bacterial pneumonia as an immunoadjuvant. Immunomodulatory adjuvant therapy is a promising strategy in treating severe pneumonia [2] . By targeting the host rather than the pathogen, immunomodulation can avoid selective pressure for the evolution of microbial resistance [32] . In a clinical study, PGRN concentrations correlated negatively with bacterial loads in patients with chronic obstructive pulmonary disease [38] . In murine models, PGRN deficiency led to severe inflammation, lung injury, and cell death in a mouse model of endotoxic shock [11, 33] , and PGRN could prevent LPS-induced acute lung injury [39] . A very recent study also demonstrated that PGRN protected lung epithelial cells from cigarette smoking-induced apoptosis [40] . All of these studies suggest that PGRN is potentially protective in pulmonary immunity in humans. Our study provided experimental evidence Figure 6 . Continued for the protective role of PGRN in reducing early mortality rate in severe pneumonia. Human subjects with higher levels of PGRN may be associated with improved outcomes in bacterial pneumonia. However, there is no available data to see whether PGRN gene or protein expression is lower at early time-points after infection in people that succumb to fulminant pneumonia. It would be very helpful to see a kinetic analysis of time of treatment after infection and the survival rates, and we acknowledge this can only be definitively established in humans with a clinical study of PGRN administration.
There are a few important limitations to this study. First, we only took pediatric patients with pneumonia to determine the expression of PGRN. Becausea pediatric cohort would not necessarily be expected to behave the same way immunologically as an adult cohort, adult patients should be studied to determine whether higher levels of PGRN are potentially protective in humans during community-acquired pneumonia. Second, the number of patients with pneumonia in this study was relatively small, and thus we could not analyze the correlation between PGRN levels and pneumonia severity. We will continue to pursue the diagnostic and prognostic value of PGRN for community-acquired pneumonia in a larger clinical study. Furthermore, the receptor(s) for PGRN and the mechanisms by which PGRN regulates pulmonary cytokine and chemokine production in pneumonia remain unknown. This needs to be further investigated. Finally, it is important to confirm that this approach of PGRN administration during bacterial pneumonia is really practical therapeutically.
In conclusion, we document that PGRN deficiency led to increased bacterial growth and dissemination accompanied by enhanced lung injury and mortality in bacterial pneumonia. This study shows for the first time that PGRN exerted its protective role by its involvement in the recruitment of pulmonary macrophages and neutrophils during bacterial pneumonia. Our data establish the feasibility for the use of PGRN as an immunomodulatory adjuvant in severe bacterial pneumonia.
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Supplementary materials are available at The Journal of Infectious Diseases online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author. , and survival was monitored. **P < .01 when compared with PGRN −/− mice treated with control solution (Kaplan-Meier analysis followed by log-rank tests). B, Bacterial counts in the lungs of PGRN −/− mice (n = 5 per group) treated with or without recombinant PGRN at 24 hours after intranasal P. aeruginosa (1 × 10 7 CFUs) challenge. *P < .05 when compared with PGRN −/− mice treated with control solution (Mann-Whitney U test). C, Wild-type (WT) mice (n = 10 per group) were intranasally treated with 10 μg of recombinant PGRN or control solution 2 hours after intranasal P. aeruginosa challenge (5 × 10 7 CFUs), and survival was monitored. **P < .01 when compared with WT mice treated with control solution (KaplanMeier analysis followed by log-rank tests). D, Bacterial counts in the lungs of WT mice (n = 5 per group) treated with or without recombinant PGRN at 24 hours after intranasal P. aeruginosa (5 × 10 7 CFUs) challenge. *P < .05 when compared with WT mice treated with control solution (Mann-Whitney U test). Abbreviations: CFU, colony-forming unit; PBS, phosphate-buffered saline; PGRN, progranulin; rPGRB, recombinant progranulin; WT, wild-type.
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